Skip Navigation



BJA Advance Access published online on March 17, 2006
British Journal of Anaesthesia, doi:10.1093/bja/ael051
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
96/5/627    most recent
ael051v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dahan, A.
Right arrow Articles by Danhof, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahan, A.
Right arrow Articles by Danhof, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Board of Management and Trustees of the British Journal of Anaesthesia 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Accepted February 5, 2006

Clinical Investigation

Buprenorphine induces ceiling in respiratory depression but not in analgesia

A. Dahan 1 *, A. Yassen 2, R. Romberg 1, E. Sarton 1, L. Teppema 1, E. Olofsen 1, and M. Danhof 2

1 Department of Anesthesiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
2 Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Gorlaeus Laboratory, Leiden, The Netherlands

* To whom correspondence should be addressed.
A. Dahan, E-mail: a.dahan{at}lumc.nl


  Abstract

Background. We measured the effect of two weight adjusted i.v. doses (0.2 mg per 70 kg and 0.4 mg per 70 kg) of the potent opioid buprenorphine on analgesia and respiratory depression in healthy volunteers. The aim of the study was to compare buprenorphine's behaviour with respect to the occurrence of ceiling (or apparent maximum) in these typical µ-opioid protein-(MOP) receptor effects.

Methods. Ten subjects (5 males) received 0.2 mg per 70 kg, 10 others (5 males) 0.4 mg per 70 kg i.v. buprenorphine. Steady-state inspired minute ventilation at a fixed end-tidal PCO2 of 7 kPa was measured before drug infusion and at regular intervals after drug infusion. Experimental pain was induced using transcutaneous electrical stimulation and a gradually increasing current. Pain tolerance was measured at regular intervals before and after drug infusion. The studies lasted 8 h.

Results. After infusion of the drug ventilation showed a rapid decline and reached peak depression between 150 and 180 min after drug administration. This effect was dose-independent with respect to timing and magnitude. At peak respiratory depression minute ventilation was 13.1 (SD 1.8) litre min-1 in the 0.2 mg group vs 12.0 (SD 1.3) litre min-1 in the 0.4 mg group (n.s.). At buprenorphine 0.2 mg a small short-lived analgesic effect was observed with a maximum increase in pain tolerance current of 6.7 (SD 2.8) mA occurring at 75 min after drug administration. Peak analgesic effect was 29% above baseline current. In contrast, buprenorphine 0.4 mg caused a large and long-lived analgesic effect with a maximum increase in pain tolerance current of 23.8 (SD 7.4) mA occurring at 130 min after drug administration. Peak analgesic effect was 160% above baseline current (0.4 vs 0.2 mg, P<0.01).

Conclusions. While buprenorphine's analgesic effect increased significantly, respiratory depression was similar in magnitude and timing for the two doses tested. We conclude that over the dose range tested buprenorphine displays ceiling in respiratory effect but none in analgesic effect.

Keywords: analgesia, ceiling; analgesics opioid, buprenorphine; complications, respiratory depression; pain; respiratory depression; opioid-induced.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
M. S. Virk, S. Arttamangkul, W. T. Birdsong, and J. T. Williams
Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization
J. Neurosci., June 3, 2009; 29(22): 7341 - 7348.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. D. Mitsis, R. J. M. Governo, R. Rogers, and K. T. S. Pattinson
The effect of remifentanil on respiratory variability, evaluated with dynamic modeling
J Appl Physiol, April 1, 2009; 106(4): 1038 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
S. Pirnay, B. Megarbane, X. Decleves, P. Risede, S. W. Borron, S. Bouchonnet, B. Perrin, M. Debray, N. Milan, T. Duarte, et al.
Buprenorphine Alters Desmethylflunitrazepam Disposition and Flunitrazepam Toxicity in Rats
Toxicol. Sci., November 1, 2008; 106(1): 64 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
K. T. S. Pattinson
Opioids and the control of respiration
Br. J. Anaesth., June 1, 2008; 100(6): 747 - 758.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. D. Hayes, W. Klein-Schwartz, and S. Doyon
Toxicity of Buprenorphine Overdoses in Children
Pediatrics, April 1, 2008; 121(4): e782 - e786.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, and M. Danhof
Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 598 - 607.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.